

Giuseppe Mancia

Editorials

1989-2019

1. **Mancia G.** Overview: economic evaluation and coronary heart disease. *Am.Heart J.* 1989,119 :775-776.
2. **Mancia G.** Neuroendocrine activation in heart failure. *Curr Opinion Cardiol* 1989,4 (Suppl.4):S42-S43.
3. **Mancia G,** Parati G. Editorial "The clinical significance of "white coat" hypertension". *Hypertension* 1990, 16 :624-626
4. **Mancia G,** Grassi G. Assessment of sympathetic cardiovascular influences in man. *Clin.Auton.Res.* 1991, 1 :246-49
5. Grassi G, Seravalle G, Calhoun D.A, Bolla GB , **Mancia G.** Physical exercise in essential hypertension. *Chest* 1992, 101:312S-315S.
6. **Mancia G.** Editorial. Autonomic modulation of the cardiovascular system during sleep. *N.Engl.J.Med.* 1993. 328 :347-349
7. **Mancia G,** Omboni S, Parati G, Santucci C, Trazzi S, Ulian U. Clinical value of ambulatory blood pressure monitoring. *Am.J Hypertens.* 1993, 6 :9S-13S
8. **Mancia G.** Home and ambulatory blood pressure monitoring. An overview. *Cardiology in the Elderly* 1993, 1 :461-463
9. **Mancia G, Di Rienzo M, Parati G Ambulatory blood Pressure use in hypertension.Research and clinical practice. Hypertension 1993, 21:520-524**
10. **Mancia G,** Parati G. Commentary on the revised British Hypertension Society Protocol for evaluation of blood pressure monitoring devices: a critique. *J.Hypertens.* 1993, 11 :595-597
11. **Mancia G.** The dilemma of benign nephrosclerosis: the hypertensiologist's view. *Am.J.Kidney Dis.* 1993,21,Suppl.2:84-86.
12. **Mancia G,** Giannattasio C, Grassi G. New aspects of antihypertensive treatment. Metabolism, the kidney and the heart. *Drugs* 1993,46 (Suppl 2):210-213.
13. Parati G, Ravogli A, **Mancia G.** Clinical use of ambulatory blood pressure monitoring: a critical appraisal. *J.Cardiovasc.Risk* 1994, 1 :108-109
14. **Mancia G,** Omboni S, Parati G , Ravogli A, Segar R, Ulian L. Ambulatory blood pressure monitoring in the diagnosis of hypertension and evaluation of antihypertensive drug efficacy. *Blood Pressure* 1994, 3 (Suppl 2): 20-22.
15. **Mancia G.** Blood pressure variability in normotensive subjects and hypertensive patients. *ACE inhibition* 1995, 4 :35-37.

16. Frolich ED, Safar M, Brunner H, **Mancia G**, Laurent S, O'Rourke M. Editorial. Structure and function of large arteries. *Hypertension* 1995, 26 :1.
17. **Mancia G**. Improving the management of hypertension in clinical practice. *J Human Hypertens* 1995, 9:S29-S31
18. **Mancia G**, Van Zwieten PA. How safe are calcium antagonists in hypertension and coronary heart disease?. *J Hypertens* 1996, 14: 13-17.
19. **Mancia G**, Giannattasio C. Benefits and costs of antihypertensive treatment. *Eur Heart J* 1996, 17 (suppl A): 25-28.
20. **Mancia G**, Cleland JGF. Health economic issues in cardiovascular disease. *Eur Heart J* 1996, 17 (suppl A): 1.
21. **Mancia,Zanchetti A Editoria,I.White coat hypertension:misnomers, misconceptions and misunderstandings J Hypertens 1996,9,:1049-1052**
22. Zanchetti A, **Mancia G**. Editorial. Benefit and cost-effectiveness of antihypertensive treatment. The actuarial vs the intervention trial approach. *J Hypertens* 1996; 14: 809-811.
23. Zanchetti A, **Mancia G**. Editorial. Debating the value of absolute versus relative risk. *J Hypertens* 1996, 14: 681.
24. Grassi G, **Mancia G**. Sympathetic activation and loss of reflex sympathetic control in mild congestive heart failure. *Circulation* 1996, 94: 2310-2311
25. Grassi G, Cattaneo BM, Seravalle G, Colombo M, Cavagnini F, **Mancia G**. Obesity and the sympathetic nervous system. *Blood Pressure* 1996, 5, Suppl.1: 43-46
26. Parati G, Ulian L, Santucci C, **Mancia G**. Reproducibility of blood pressure measurements. *Blood Pressure Monit* 1996; 5:36-38
27. Parati G, Frattola A, Omboni S, **Mancia G**, M. Di Rienzo. Analysis of heart rate and blood pressure variability in the assessment of autonomic regulation in arterial hypertension. *Cli Sci* 1996; 91:129-132
28. Parati G, Zanchetti A, **Mancia G**. One hundred years of blood pressure measurements: a tribute to Scipione Riva-Rocci. *Blood Pressure Monitoring* 1996; 1:S3-S7
29. **Mancia G**, Giannattasio C, Grassi G. Arterial compliance in Cardiovascular Diseases. In: *Ace Report* 1997:7-11
30. Zanchetti A, **Mancia G**. Editors' corner: strategies for antihypertensive treatment decisions: how to assess benefits. *J. Hypertens* 1997, 15: 215-216
31. Zanchetti A, **Mancia G**. Strategies for antihypertensive treatment decisions: how to assess benefits. *J. Hypertens* 1997, 15: 215-216
32. **Mancia G**, G. Grassi. Antihypertensive treatment: why and how. *Arch Maladies Coeur Vaisseaux*, 1997, 90: 41-44
33. **Mancia G**, G.Grassi. Editorial. Combination treatment in antihypertensive drug trials. *Cardiov. Drugs Ther* 1997, 11: 517-518
34. Hansson L, **Mancia G**. Evaluation of endpoints in hypertension. *Blood Pressure* 1997, Suppl.2: 5
35. Parati G, Leonetti G, **Mancia G**. Blood pressure, aging and variability. *Eur Heart J* 1997,18: 889-890
36. **Mancia G**, Paleari F, Parati G. Editorial: Early diagnosis of diabetic autonomic neuropathy. Present and future Approaches. *Diabetologia* 1997, 40: 482-484

37. **Mancia G**, Giannattasio C. Editorial: Studies on alterations of arterial and arteriolar structure and function in hypertension and diabetes. *Eur.Heart.J* 1997, 18: 1049-1050
38. Frolich ED, Safar M, Brunner H, **Mancia G**, London G, O'Rourke M. Editorial. Commentary – Third Workshop on structure and function of large arteries. *Hypertension* 1998, 32, 155
39. **Mancia G**, Grassi G. Antihypertensive treatment: past, present and future. *J. Hypertens* 1998, 16, suppl. 1: S1-S7
40. **Mancia G**, Failla M, Grappiolo A, Giannattasio C. Present and future role of combination treatment in hypertension. *J Cardiovasc. Pharmacol.* 1998, 31 (Suppl.): S41 - S44
41. Hansson L, **Mancia G**. Do European hypertensives get optimal treatment?. *Int. J Clin Practice* 1998, Suppl. 98:2
42. **Mancia G**, Lanfranchi A, Turri C, Grassi G. Can surrogate end-points predict the prognosis of hypertensive patients. *J. Hypertension* 1998, 16 (Suppl 5) : S3-S7
43. Saino A, **Mancia G**. Angiotensin II and coronary sympathetic vasodilatation. *Circulation* 1998, 97 :1873-1874
44. Zanchetti A, **Mancia G**. Looking back on three years of editorship. *J.Hypertens.* 1998, 16:1
45. Fröhlich ED, Safar ME, Brunner H, **Mancia G**, London G, O'Rourke M. Editorial Commentary. Third Workshop on Structure and Function of Large Arteries: Part I. *Hypertension* 1998;32:155
46. Redaelli A, Mircoli L, Mori I, **Mancia G**, Ferrari AU. Are autonomic influences important in modulating the release of nitric oxide in conscious normotensive rats?. *J.Hypertens.* 1998, 16 (Suppl.8) :525-529
47. Parati G, **Mancia G**. Assessing effective and balanced twenty-four-hour blood pressure reduction by treatment: methodological aspects. *J.Hypertens.* 1999,17:455-456
48. O'Rourke M, **Mancia G**. Editorial. Arterial stiffness. *J.Hypertens* 1999, 17 :1-4

49. **Mancia M**, Grassi G, Giannattasio C, Seravalle G. Sympathetic activation in the pathogenesis of hypertension and progression of organ damage. *Hypertension* 1999, 34: 724-728
50. **Mancia M**, Grassi G. New perspectives in cardiovascular risk factors, end-organ damage and sympathetic activity in human hypertension. *Latest Trends in Hypertension*, 1999; n.6: 2-6
51. **Mancia G**. New trends in pharmacotherapy of human hypertension. *Recent Prog Med* 1999, 90 :648-649
52. **Mancia G**, Stella ML, Grassi G. New drugs in the treatment of hypertension. *Curr. Opin. Cardiol.* 1999,14:375-380
53. Grassi G, **Mancia G**. Sympathetic overactivity and exercise intolerance in heart failure: a cause-effect relationship. Editorial, *Eur Heart J.* 1999,20:854-855
54. **Mancia G**, Bertinieri G. Influence of smoking on baroreceptor function: 24h measurements. *J.Hypertens.* 1999, 17 :1507-1508
55. Zanchetti A , **Mancia G**. Editorial: Evidence based medicine: an educational instruction or a standard for implementation? *J.Hypertens.* 1999, 17 :1507-1508
56. **Mancia G**. Editorial "White coat effect. Innocuous or adverse phenomenon?" *Europ Heart J* 2000, 21 :1647-1648

57. **Mancia G.** 1 – imidazoline receptors: clinical relevance in hypertensive patients. *Am J. Hypertens* 2000, 13:83S
58. **Mancia G.** European Society of Hypertension. A note from the President. *J. Hypertens* 2000,18:1701-1703
59. Zanchetti A, **Mancia G.** The old Editor's new prologue. *J Hypertens.* 2000;18:1-2.
60. Mancia G, Segna R, Grassi G, Cesana G, Zanchetti A Editorial. Defining ambulatory and home blood pressure normality. Further considerations on data from PAMELA study *JHypertens* 2001,19: 955-999
61. Parati G, **Mancia G.** Editorial: Ambulatory blood pressure monitoring in clinical practice. *J. Hypertens.* 2002, 20:1925-1927
62. **Mancia G,** Grassi G. Systolic and diastolic blood pressure control in antihypertensive drug trials. *J.Hypertension* 2002, 20:1461-1464
63. **Mancia G,** Grassi G. Secondary prevention of stroke: Old and new evidence. *Aging* 2002, 14, 216-220
64. Parati G, Ongaro G, Glavina F, Di Rienzo M, **Mancia G.** Sleep apnoea and hypertension. *Curr Opinion Nephrol. Hypertens* 2002, 11: 201-204
65. Zanchetti A, **Mancia G.** Coping with the challenges of the next four years. *J. Hypertension* 2002, 20, 1-2
- 31 Zanchetti , **Mancia G.** News, reminiscences and perspectives: a new section of the Journal of Hypertension. *J.Hypertens* 2002, 20:1033
- 32 Parati G, **Mancia G.** Hypertension staging through ambulatory blood pressure monitoring. *Hypertension* 2002; 40:792-794
- 33 Zanchetti A, **Mancia G.** New year, new challenges. *J. Hypertens* 2003, 21:1-2
- 34 Zanchetti A, **Mancia G.** The ALLHAT trial: a verdict or a challenge? *J.Hypertens* 2003, 21:223
- 35 Parati G, **Mancia G.** Editorial: "White coat effect: semantics, assessment and pathophysiological implications. *J Hypertens.* 2003, 21:481-486
- 36 Grassi G, **Mancia G.** Neurogenic hypertension: is the enigma of its origin near the solution? *Hypertension* 2003, 170:145-155
- 37 Grassi G, Foglia G, Dell'Oro R, Quarti-Trevano F, Seravalle , Mancia G Salt intake and sympathetic activity *Circulation* 2003,107,e108
- 38 Reims H, Kjeldsen SE, **Mancia G.** Home blood pressure monitoring. *Blood Press.* 2003; 12: 187-188
- 39 **Mancia G,** Weber M. Introduction. A new dawn in cardiovascular protection: blood pressure lowering through AT1 blockade. *J.Hypertens* 2003; 21 (Suppl 6): S1-S2
- 40 Reims HM, Kjeldsen SE and **Mancia G.** Home blood pressure monitoring. *J Hypertens* 2003, 23:1437-1439..
- 41 **Mancia G.** Editorial *J Hypertens* 2003;21 (suppl. 5) S1.
- 42 Zanchetti A, **Mancia G.** Looking back, looking forward. *J. Hypertens.* 2004, 22: 1-2
- 43 **Mancia G,** Grassi G. Sympathetic nervous system-renin-angiotensin interactions. *SNS Report* 2004, Vol. n.11: 2-4

- 44 **Mancia G.** Low-dose combination therapy: ESH/ESC versus JNC7 guidelines. *New Frontiers in Hypertension* 2004; 13: 7
- 45 **Mancia G, Grassi G.** The Hypertension Guidelines of the Seventh Joint National Committee – A critical Review. *High Blood Press Cardiovasc Prev* 2004; 11:55-59
- 46 Kjeldsen SE, Reims HM, **Mancia G.** Commentary. *Evidence Based Cardiovasc Medicine.* 2004;8:204-205.
- 47 **Mancia G, Zanchetti A.** One hundred years of auscultatory blood pressure: commemorating N.S. Korotkoff. *J. Hypertens.* 2005;23:1-2.
- 48 Grassi G, Quarti F, **Mancia G.** Hypertension, antihypertensive treatment and stroke prevention. *Neurol Sci* 2005, 26:S222-S223
- 49 **Mancia G,** Symposium: “A straightforward strategy for all grades of hypertension”. *J. Human Hypertens.* 2005:19, S1
- 50 Reims HM, Kjeldsen SE and **Mancia G.** Home blood pressure monitoring. *J Hypertens* 2005, 23:1437-1439.
- 51 Mancia G,Zanchetti A One hundred years of auscultatory blood pressure monitoring:commemorating NS Korotkoff *J Hypertens* 2005,23:1-2
- 52 **Mancia G, Grassi G.** Efficacy of antihypertensive treatment which endpoints should be considered? *Nephrol Dial Transplant* 2005, 20: 2301-2303
- 53 Zanchetti A, **Mancia G.** On the state of the Journal. *J. Hypertens* 2006, 24: 1
- 54 **Mancia G, Scopelliti F, Grassi G.** Hypertension and the Heart. *Semin Cardiothorac Vasc Anesth.* 2006; 10:198-202.
- 55 **Mancia G.** Effective ambulatory blood pressure control in medical practice: good news to be taken with caution. *Hypertension* 2007; 49:17-18.

- 56 **Mancia G.** ADVANCE in the Prevention of Cardiovascular Disease in Diabetic Patients. *Am J Hypert* 2007; 20:1S-2S
- 57 **Mancia G.** Blood pressure and Glucose Control in Patients with Diabetes. *Am J Hypert* 2007; 20:3S-8S
- 58 **Mancia G, Grassi G.** Editorial. The new European Society of Hypertension/European Society of Cardiology (ESH/ESC) Guidelines. *Therapeutic Advances in Cardiovascular Disease* 2008, 2:5-12.
- 59 Grassi G and **Mancia G.** The ADVANCE Trial: results, clinical implications and perspectives. *E-Journal* 2008;Vol. 6, N° 28.
- 60 Fujita T, **Mancia G.** A new dawn in cardio and vascular protection V. cardiovascular high-risk patients: treat to protect. *Medscape J Med.* 2008, 10(Suppl):S1.
- 61 Grassi G, Quarti-Trevano F, Dell'Oro R, **Mancia G.** Essential hypertension and the sympathetic nervous system. *Neurol Sci.* 2008, 29:S33-S36.
- 62 **Mancia G.** The TALENT Study. *European Cardiology* 2008;4:75-78.
- 63 Zanchetti A, **Mancia G.** The dilemma of placebo controlled studies: scientific evidence, guidelines, ethics and regulatory recommendations. *J Hypertens.* 2009;27:1-2.
- 64 Grassi G, **Mancia G.** Cardiometabolic risk in high-normal blood pressure state: mechanistic insights. *J Hypertens.* 2009;27:28-30

- 65 **Mancia G.** Prevention of risk factors: beta-blockade and hypertension. *Eur Heart J Suppl.* 2009;11 (Suppl.A):A3-A8.
- 66 **Mancia G,** Grassi G. Editorial. Management of very elderly hypertensives: the HYVET study. *Aging Clin Exp Res.* 2009;20(6):494-495
- 67 **Mancia G.** The threat of diabetes to public health. Introduction. *J Hypertens.* 2009; 27 (Suppl 1).S1.
- 68 **Mancia G,** Grassi G. Protection of patients with diabetes, with or without hypertension: implications of ADVANCE for clinical practice. *J Hypertens.* 2009; 27 (Suppl 1):S19-S23.
- 69 Grassi G, **Mancia G.** Implementation of new evidence into hypertension guidelines: the case of the ONTARGET and TRANSCEND trial. *J Hypertens.* 2009;27 (Suppl. 2):S40-S44.
- 70 **Mancia G.** Defining blood pressure goals: is it enough to manage total cardiovascular risk?. *J Hypertens.* 2009; 27 (Suppl 5):S3-S8.
- 71 **Mancia G,** Seravalle G, Grassi G. Therapeutic strategies to lower and control high blood pressure. *Arch Med Sci* 2009; 5, 2A:S294-S299.
- 72 **Mancia G,** Sega R, Bombelli M, Quarti-Trevano F, Facchetti R, Grassi G. Should white-coat hypertension in diabetes be treated? *Pro. Diabetes Care* 2009;32(Suppl 2): S305-S309.
- 73 **Mancia G.** Editorial Commentary. Comparing methods for assessing cardiovascular risk. *J Hypertens.* 2009; 27:2342-2343.
- 74 **Mancia G,** Corrao G. Targeting blood pressure in the management of total cardiovascular risk. *Eur Heart J Supplements* 2009; 11(Suppl F):F27-F32
- 75 **Mancia G,** Grassi G. Orthostatic hypotension and cardiovascular risk: defining the epidemiological and prognostic relevance. *Eur Heart J* 2010;31:12-14.
- 76 **Mancia G,** Parati G, Zanchetti A. Electrical carotid baroreceptor in resistant hypertension. *Hypertension* 2010; 55:607-609.
- 77 **Mancia G,** Parati G. Home blood pressure monitoring: a tool for better hypertension control. *Hypertension* 2011;57:21-23.
- 78 **Mancia G.** Prognostic value of long-term blood pressure variability: the evidence is growing. *Hypertension* 2011; 57:141-143.
- 79 **Mancia G.** Angiotensin receptor antagonists and increased risk of cancer. Further evidence against. *J Hypertens.* 2011;29:653-654.
- 80 **Mancia G,** Giannattasio C. Endothelium in polycythemia secondary to obstructive lung disease. *J Appl Physiol.* 2011;110:1158-1159.
- 81 Grassi G, **Mancia G.** Prevention of Microalbuminuria in Diabetes Mellitus: Results of the ROADMAP Trial. *Curr. Hypertens Rep.* 2011;13:265-267
- 82 Grassi G, **Mancia G.** The PAMELA study – results and perspectives. An article from the e-journal of the Council *Cardiol Practice.* 2011;10 n.5
- 83 **Mancia G.** Assessing antihypertensive treatment by real life data. *J Hypertens* 2012, 30:46-47
- 84 **Mancia G** Antihypertensives in octogenarians *BMJ* 2012: 344, d7293
- 85 **Mancia G.** Hypertension: Does antihypertensive treatment have long-term benefits? *Nat Rev Cardiol.* 2012; 9:130-132 .

- 86 Zanchetti A, **Mancia G**. Longing for clinical excellence: a critical outlook into the NICE recommendations on hypertension management - is nice always good? *J Hypertens*. 2012;30:660-668.
- 87 Grassi G, **Mancia G**. New therapeutic approaches for resistant hypertension. *J. Nephrol* 2012; 25:276-281
- 88 Cockcroft J, **Mancia G**. Vascular aging: shifting the paradigm of risk assessment and reduction in hypertension. *J Hypertens* 2012, 30(Suppl 1):S1-S2
- 89 **Mancia G**. Reporting blood pressure effects of antihypertensive treatment in scientific papers: are guidelines needed? *J Hypertens* 2012, 30:1307-1309
- 90 **Mancia G** Additional drug treatment in resistant hypertension: need for randomized studies. *J Hypertens* 2012; 30: 1514-1515
- 91 Grassi G, Seravalle G, Brambilla G, Bombelli M, Dell'Oro R, Gronda E, **Mancia G**. Novel antihypertensive therapies: renal sympathetic nerve ablation and carotid baroreceptor stimulation. *Curr Hypertens Rep* 2012;14:567-572
- 92 Grassi G, **Mancia G**. Tailoring antihypertensive drug treatment to body size. *Nat. Rev. Endocrinol.* 2013; 9, 141-143.
- 93 **Mancia G**. Ambulatory Central Blood Pressure. A new opportunity for mechanistic and clinical cardiovascular research. *Hypertension*. 2013;61:1148-1149.
- 94 **Mancia G**. BP control: is the trend favourable? *J Hypertens*. 2013;31:1094-1095
- 95 **Mancia G**. Ambulatory Central Blood Pressure. A New Opportunity for Mechanistic and Clinical Cardiovascular Research. Editorial Commentary. *Hypertension*. 2013;61:1148-1149.
- 96 Grassi G and **Mancia G**. Renal nerve ablation as a tool for studying the interactions between arterial stiffness, blood pressure and sympathetic drive: weight of the evidence. *J. Hypertens*. 2013;31:1782-1784
- 97 Kallistratos MS, Manolis AJ, **Mancia G**. Blood pressure. The forgotten factor in previous and recent studies regarding anticoagulation in atrial fibrillation. *Int J of Cardiology*. 2013;160:4434-4435.
- 98 **Mancia G**. Strength and limitations of the JNC8 hypertension guidelines. *Nat Rev Cardiol* 2014;11:189-190..
- 99 **Mancia G**. The New American Guidelines on Hypertension.:A favourable opinion. *J Clin Hypertens* 2014;16:255-256.
- 100 **Mancia G**, Fagard R. Hypertensive urgencies and emergencies: reducing the gap between guidelines and clinical practice. *J Hypertens*. 2014;32:1911
- 101 **Mancia G**, Fagard R. Have we attained the right control of hypertension? Consequences of the 2013 European Society of Hypertension/European Society of Cardiology and Eighth Joint National Committee recommendations. *J Hypertens*. 2014;32:1907.
- 102 Caravita S, Faini A, Bilo G, Villafuerte FC, Macarlupu JL, Lang M, Salvioni E, Revera M, Giuliano A
- 103 **Mancia G** Introduction to a compendium on hypertension *Circ Res* 2015,116:923-924
- 104 **Mancia G**. Preventing new onset diabetes in thiazide-treated patients. *Lancet Diabetes Endocrinol* 2016,4:90-92.

- 105 Kjeldsen SE, Narkiewicz K, Hedner T, **Mancia G**. The SPRINT study: Outcome may be driven by difference in diuretic treatment demasking heart failure and study design may support systolic blood pressure target below 140 mmHg rather than below 120 mmHg. *Blood Pressure*. 2016,25:63-66
- 106 Kjeldsen SE, Berge E, Bangalore S, Messerli FH, Mancia G, Holzhauser B, Hua TA, Zappe D, Zanchetti A, Weber MA, Julius S. No evidence for a J-shaped curve in treated hypertensive patients with increased cardiovascular risk: The VALUE trial. *Blood Pressure*. 2016,25:83-93.
- 107 Chalmers J, Woodward M, Borghi C, Manolis A, **Mancia G**. Strategies to meet the need for long-term data. *J. Hypertens* 2016,34:1473-1479.
- 108 Grassi G, **Mancia G**, Nilsson PM. Specific Blood Pressure Targets for patient with diabetic nephropathy? *Diabetes Care* 2016,39 (suppl. 2): S228-233
- 109 Kjeldsen SE, **Mancia G**. Unobserved automated office blood pressure measurement in the Systolic Blood Pressure Intervention Trial (SPRINT): systolic blood pressure treatment target remains below 140 mmHg. *Eur Heart J Cardiovasc Pharmacother*. 2016,2:79-80.
- 110 **Mancia G**. Hypertension: Blood pressure targets for elderly patients: new SPRINT data. *Nat Rev Nephrol*. 2016,12:450-452.
- 111 **Mancia G** Should BP reduction be aggressive in patients with coronary disease *Lancet* 2016;388, 2061-2062
- 112 **Mancia G**. The SPRINT trial: Part II (Cons) of a two-part Expert Analysis. ACC online. <http://www.acc.org/latest-in-cardiology/articles/2015/12/01/10/04/the-sprint-trial-cons>
- 113 **Mancia G** and Grassi G. The Heterogeneous Nature of White-Coat Hypertension* *J Am Coll Cardiol*. 2016,68:2044-2046.
- 114 **Mancia G**. Clinical significance of white coat hypertension. *J Hypertens* 2016,34:623-626
- 115 Volpe M, Battistoni A, **Mancia G**. Angiotensin II-linked Hypothesis to Understand the Advantage of the Co-evolution of Hypertension and Malaria: "Sympathy for the Devil". *Circ Res*. 2016,119:1046-1048.
- 116 Mancia G Editorial. Should blood pressure reduction be aggressive in patients with hypertension and coronary disease? *Lancet* 2016,388:2061-2062
- 117 Grassi G, **Mancia G**. Quarter dose combination therapy. Good news for blood pressure control. *Hypertension* 2017,70:32-34..
- 118 Tadic M, Cuspidi C, Pencic-Popovic B, Celic V, **Mancia G**. The influence of night-time hypertension on left ventricular mechanics. *Int J Cardiol*. 2017,243:443
- 119 Grassi G, **Mancia G** Hypertension. Quarter dose quadipill combinations *Nat Rev Nephrol* 2017,13s:266-267
- 120 Tsioufis C, Mahfoud F, **Mancia G**, Tousoulis D. Editorial: Uncontrolled Hypertension and Related Comorbidities: A Clinician's Update. *Corr Vasc Pharmacol*. 2017,16:3-4

- 121 Grassi G, **Mancia G**. "Keep an eye" on the heart: retinal microcirculation disarray in congestive heart failure. *Eur Heart J* 2018,39:57-59.
- 122 **Mancia G**. Editor's Corner. Highlights of the issue. *J Hypertens* 2018, 36:1209-1211
- 123 Mancia G**. Editor's Corner. Highlight of the issue. *J Hypertens* 2018,36:1435-1426
- 124 **Mancia G**. Editor's Corner. Highlights of the issue. *J Hypertens* 2018;36: 1611-1613
- 125 Morganti A, **Mancia G**. Resistant hypertension: Renal denervation or intensified medical treatment? *Eur J Intern Med*. 2018;50:6-11
- 126 Tsioufis C, Mahfoud F, **Mancia G**, Tousoulis D. Editorial: Uncontrolled Hypertension and Related Comorbidities: A Clinician's Update. *Curr Vasc Pharmacol*. 2018, 16, 3-4
- 127 **Mancia G**. Target blood pressure and kidney protection. *Lancet & Endocrinology* 2018,6:521-523
- 128 Seravalle G, **Mancia G**, Grassi G. Sympathetic nervous system, Sleep and Hypertension. *Current Hypertension Report* 2018; 20:74.
- 129 **Mancia G**. Ed Corner .Highlights of the issue. *J Hypertens*. 2018;36:2281-2283
- 130 **Mancia G**. Renal nerve ablation. *Eur Heart J* 2018, 39:4060-4061
- 131 Grassi G, **Mancia G**. Masked Uncontrolled Hypertension. *Hypertension*. 2019,;73:39-41.
- 132 Kjeldsen SE, **Mancia G**. Unattended automated office vs. ambulatory blood pressure in people with high cardiovascular risk: implications for understanding the SPRINT results. *J Hypertens*. 2019,37:6-8
- 133 **Mancia G**. Editor's corner.Highlights of the January issue. *J Hypertens*. 2019,37:1-3.
- 134 **Mancia G**. Editor's corner.Highlights of the February issue. *J Hypertens*. 2019,37:227-228
- 135 **Mancia G**.Editor's corner. Highlights of the March issue. *J Hypertens*. 2019,37:457-458
- 136 **Mancia G**. Editor's corner. Highlights of the April issue. *J Hypertens* 2019;37:657-659.
- 137 **Mancia G**, Hall JE. Introduction to a Compendium on the Pathophysiology and Treatment of Hypertension. *Circ Res* 2019,124:967-968
- 138 **Mancia G**. Editor's corner. Highlights of the May issue. *J Hypertens* 2019,37:863-864
- 139 **Mancia G**. Editor's corner. Highlights of the June issue. *J Hypertens* 2019,37:1099-1101
- 140 **Mancia G**. Editor's corner. Highlights of the July issue. *J Hypertens* 2019, 37:1309-11.
- 141 **Mancia G**. Editor's corner.Highlights of the August issue. *J Hypertens*. 2019,37:1539-1540.
- 142 **Mancia G** . Editor's corner. Highlights of the September issue. *Journal of Hypertens*.2019, 37:1735-1736
- 143 **Mancia G**. Editor's corner. Highlights of the October issue. *J Hypertens* 2019; 37:1915-1916
- 144 **Mancia G** **Target blood pressure values in the Us and European guidelines.Are they truly similar? J Clin Hypertens 2019, 21.1602-1603**
- 145 **Mancia G** **Priorities for hypertension prevention and/or management over the coming 5 years:an International view-point WHL Newsletter 2019,165:8-9**
- 146 **Mancia G** **Editor's corner. Highlights of the November issue J Hypertens 2019,37:2123-2124**

147 Mancia G Editor's corner.Highlights of the December issue J Hypertens 2019, 37:2305-2306

148 Mancia G Editor's corner.Highlights of the January issue J Hypertens 2019, 38,:1-2